Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F13%3A10139484" target="_blank" >RIV/00179906:_____/13:10139484 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/13:10139484

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.aller.2012.02.006" target="_blank" >http://dx.doi.org/10.1016/j.aller.2012.02.006</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.aller.2012.02.006" target="_blank" >10.1016/j.aller.2012.02.006</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy

Popis výsledku v původním jazyce

Background: CD163 is the monocyte/macrophage receptor for haptoglobin-haemoglobin complexes. The aim of this study was to assess the kinetics in the expression of CD163 on monocytes and the concentration of soluble sCD163 in serum of psoriatic patients in order to examine the effect of Goeckerman therapy. Methods: sCD163 was measured in 71 patients before and after therapy, and in 57 healthy donors. A subgroup of 40 patients and 25 controls was used to assess the expression of membrane CD163. sCD163 wasevaluated by ELISA. Flow cytometry method was used to determine the expression of membrane CD163 on monocytes, expressed as mean fluorescence index (MFI). Results: Before therapy, the serum level of sCD163 was significantly higher in our patients than in controls (P=0.0154). However, we observed a profound decrease in sCD163 in our patients after therapy (P=0.0037). Similar to sCD163, pre-treatment expression of CD163 on monocytes was significantly more enhanced in patients than that in

Název v anglickém jazyce

Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy

Popis výsledku anglicky

Background: CD163 is the monocyte/macrophage receptor for haptoglobin-haemoglobin complexes. The aim of this study was to assess the kinetics in the expression of CD163 on monocytes and the concentration of soluble sCD163 in serum of psoriatic patients in order to examine the effect of Goeckerman therapy. Methods: sCD163 was measured in 71 patients before and after therapy, and in 57 healthy donors. A subgroup of 40 patients and 25 controls was used to assess the expression of membrane CD163. sCD163 wasevaluated by ELISA. Flow cytometry method was used to determine the expression of membrane CD163 on monocytes, expressed as mean fluorescence index (MFI). Results: Before therapy, the serum level of sCD163 was significantly higher in our patients than in controls (P=0.0154). However, we observed a profound decrease in sCD163 in our patients after therapy (P=0.0037). Similar to sCD163, pre-treatment expression of CD163 on monocytes was significantly more enhanced in patients than that in

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Allergologia et Immunopathologia

ISSN

0301-0546

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

ES - Španělské království

Počet stran výsledku

5

Strana od-do

158-162

Kód UT WoS článku

000320343200004

EID výsledku v databázi Scopus

—